Jianmin, Ping An and InCube Labs all contributed to a round that will fund phase 1 clinical trials for Fe3 Medical's iron deficiency patch.
Fe3 Medical, the US-based developer of a transdermal patch to treat iron-deficiency anaemia, closed an $11m series B round co-led by pharmaceutical company Jianmin Pharmaceuticals on Wednesday.
Jianmin co-led the round with Ping An Ventures, the venture capital arm of insurance firm Ping An, and private equity firm HG Capital. The round also included InCube Labs, the life sciences R&D laboratory that initially developed Fe3’s technology.
The capital will support clinical trials and regulatory submissions required for Fe3’s transdermal patch,…
